RNS Number : 8466E
Immupharma PLC
21 July 2016
 

RNS : FOR IMMEDIATE RELEASE

21 JULY 2016

 

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

TR1 NOTIFICATION OF MAJOR INTEREST BY AVIVA

 

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Aviva plc ("Aviva"). Aviva's holding in ImmuPharma is now confirmed at a total of 11,169,942 Ordinary Shares which equates to a current position in the Company of 9.17%.

 

Full disclosure of the TR1 is shown below:

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

ImmuPharma plc  

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

√

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other (please specify):    



3. Full name of person(s) subject to the
notification obligation: iii

Aviva plc & its subsidiaries    

4. Full name of shareholder(s)
 (if different from 3.):iv

Registered Holder:

 

BNY Norwich Union Nominees Limited
628,858*

 

Chase (GA Group) Nominees Limited
7,696,271*

 

State Street Nominees Limited
1,413,511*

 

*denotes direct interest  

 

Chase (GA Group) Nominees Limited
627,539

 

Chase Nominees Limited
275,292

 

Vidacos Nominees Limited
528,471

 

5. Date of the transaction and date on
which the threshold is crossed or
reached: v

19 July 2016

6. Date on which issuer notified:

20 July 2016

7. Threshold(s) that is/are crossed or reached: vi, vii

8% to 7% Change at Direct Interest Level

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

 

GB0033711010

11,224,776

11,224,776

11,169,942

9,738,640

1,431,302

7.997%

1.175%



B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date xiii

Exercise/
Conversion Period xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights






 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 










 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

11,169,942

9.172%

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-

 

Aviva Investors Global Services Limited:

·      Aviva plc (Parent Company)

·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 


Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will cease to hold:


12. Date on which proxy holder will cease to hold
voting rights:




13. Additional information:


Figures are based the revised total number of voting rights of 121,781,219 as per the recent Confirmation of EIS and VCT Qualifying Status and Issue of Equity announcement of 01 March 2016.

 

14. Contact name:

James Clark, Aviva plc

15. Contact telephone number:

 01603 683853

 

 

 

 

 

 

 

-Ends-

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman


Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

        + 44 (0) 7721 413496

 

 

 

Panmure, Gordon & Co., (NOMAD & Broker)

 

+44 (0) 20 7886 2500

Fred Walsh, Duncan Monteith, Corporate Finance

Charles Leigh-Pemberton, Corporate Broking

 

 

Northland Capital Partners Limited (Joint Broker)

Patrick Claridge, David Hignell, Corporate Finance

Rob Rees, Corporate Broking

 

 

                                                  

 

 

 

+44 (0)20 3861 6631




 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLDFLBLQDFLBBV ]]>